About the Feasibility of Personalized Medicine in a Low Income Country?


Personalized medicine is the result of the research made on the field of molecular biology. Lung cancer was mainly concerned with the establishment of many oncogenic drivers. Nowadays, the pathologist is facing a dilemma because of the multiplicity of therapeutic targets and molecular ones and the small size of specimen performed. In fact, 75% of lung cancer are diagnosed on biopsic samples. According to the recommendations of the 2013 International Group Study of Lung Cancer (IASLC), sequential analyses of Epidermal growth factor (EGFR) and anaplastic lym- phoma kinase (ALK) are necessary on adenocarcinomas, non small cell carcinomas not otherwise specified and non small cell carcinomas favor adenocarcinomas. Many interrogations are reported concerning the cost effectiveness of the diagnostic techniques and the targeted treatments. We wondered about the further feasibility of such a technique in a low income country by trying to explore the representativity of the samples. In our hospital, bronchoscopic biopsies are diagnostic in 75% of the cases. We receive a mean of 4 samples. 68% of the samples are tumoral. Immuno-histochemistry is performed in 68% of the cases with a mean of 2 antibodies used and 8% of the biopsies are non interpretable because of the small size of specimen. Concerning transthoracic biopsies, 20% are non contributive because of necrosis or the small size. We receive a mean of 1 sample with a mean size of 6 millimeters. Immunohistochemistry is performed in 71% of the cases with the mean of 2 antibodies. In addition to the scientific, pharmacoeconomic and ethic problems induced by targeted therapies in low income countries, each institution should optimize the use of the specimen received and the technical conditions in order to be ready to answer to the IASLC recommendation.

Share and Cite:

Mlika, M. , Braham, E. , Laabidi, S. , Boussen, H. and Mezni, F. (2015) About the Feasibility of Personalized Medicine in a Low Income Country?. Open Journal of Social Sciences, 3, 41-45. doi: 10.4236/jss.2015.35007.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Public Health Minister of Tunisia (1999-2003) North Tunisia Cancer Register. 71.
[2] Travis, W.D., Brambilla, E., Noguchi, M., Nicholson, A.G., Geisinger, K., Yatabe, Y., et al. (2013) Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Archives of Pathology & Laboratory Medicine, 137, 668-684. http://dx.doi.org/10.5858/arpa.2012-0263-RA
[3] Lee, A.L., Ng, V.W., Gao, S., Hedrick, J.L. and Yang, Y.Y. (2015) Injectable Biodegradable Hydrogels from Vitamin D-Functionalized Polycarbonates for the Delivery of Avastin with Enhanced Therapeutic Efficiency against Metastatic Colorectal Cancer. Biomacromolecules, 16, 465-475.
[4] Kim, H.S., Lee, G.W., Kim, J.H., Kim, H.Y., Kwon, J.H., Song, H.H., Kim, H.J., Jung, J.Y., Jang, G., Choi, D.R., Park, S.M., Shin, T.R., Lee, H.S. and Zang, D.Y. (2010) A Phase II Study of Pemetrexed and Carboplatin as a Salvage Therapy for Platinum-Pretreated Patients with Non-Small Cell Lung Cancer. Lung Cancer, 70, 71-76. http://dx.doi.org/10.1016/j.lungcan.2009.12.015
[5] Pao, W., Wang, T.Y., Riely, G.J., et al. (2005) KRAS Mutations and Primary Resistance of Lung Adenocarcinoma to Gefitinib or Erlotinib. PLoS Medicine, 2, e17.
[6] Adamson, R.T. (2013) Biomarkers and Molecular Profiling in Non-Small Cell Lung Cancr: An Expanding Role and Its Managed Care Implications. American Journal of Managed Care, 19, S398-S407.
[7] Hynes, N.E. and Lane, H.A. (2005) ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors. Nature Reviews Cancer, 5, 341-354. http://dx.doi.org/10.1038/nrc1609
[8] Suda, K., Tomizawa, K. and Mitsudomi, T. (2010) Biological and Clinical Significance of KRAS Mutations in Lung Cancer: An Oncogenic Driver That Contrasts with EGFR Mutation. Cancer and Metastasis Reviews, 29, 49-60. http://dx.doi.org/10.1007/s10555-010-9209-4
[9] Carr, L.L., Finigan, J.H. and Kern, J.A. (2011) Evaluation and Treatment of Patients with Non-Small Cell Lung Cancer. Medical Clinics of North America, 95, 1041-1054.
[10] Mitsudomi, T. and Yatabe, Y. (2007) Mutations of the Epidermal Growth Factor Receptor Gene and Related Genes as Determinants of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Sensitivity in Lung Cancer. Cancer Science, 98, 1817-1824. http://dx.doi.org/10.1111/j.1349-7006.2007.00607.x
[11] Berardi, R., Santoni, M., Morgese, F., Ballatore, Z., Savini, A., Onofri, A., et al. (2013) Novel Small Molecule EGFR Inhibitors as Candidate Drugs in Non-Small Cell Lung Cancer. OncoTargets and Therapy, 6, 563-576. http://dx.doi.org/10.2147/OTT.S28155
[12] Cataldo, V.D., Gibbons, D.L., Pérez-Soler, R. and Quintás-Cardama, A. (2011) Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine, 364, 947-955. http://dx.doi.org/10.1056/NEJMct0807960
[13] Mao, C., Qiu, L.X., Liao, R.Y., Du, F.B., Ding, H., Yang, W.C., et al. (2010) KRAS Mutations and Resistance to EGFR-TKIs Treatment in Patient with Non-Small Cell Lung Cancer: A Meta-Analysis of 22 Studies. Lung Cancer, 69, 272-278. http://dx.doi.org/10.1016/j.lungcan.2009.11.020
[14] Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., et al. (2007) Identification of the Transforming EML4-ALK Fusion Gene in Non-Small-Cell Lung Cancer. Nature, 448, 561-566. http://dx.doi.org/10.1038/nature05945
[15] Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., et al. (2007) Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell, 131, 1190-1203. http://dx.doi.org/10.1016/j.cell.2007.11.025
[16] Takeuchi, K., Choi, Y.L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., et al. (2009) KIF5B-ALK, a Novel Fusion Oncokinase Identified by Immunohistochemistry-Based Diagnostic System for ALK-Positive Lung Cancer. Clinical Cancer Research, 15, 3143-3149. http://dx.doi.org/10.1158/1078-0432.CCR-08-3248
[17] Pan, Y., Zhang, Y., Li, Y., Hu, H., Wang, L., Li, H., Wang, R., Ye, T., et al. (2014) ALK, ROS1 and RET Fusions in 1139 Lung Adenocarcinomas: A Comprehensive Study of Common and Fusion Pattern-Specific Clinicopathologic, Histologic and Cytologic Features. Lung Cancer, 84, 121-126.
[18] Bepler, G., Zinner, R.G., Moon, J., Calhoun, R., Kernstine, K., Williams, C.C., et al. (2014) A Phase 2 Cooperative Group Adjuvant Trial Using a Biomarker-Based Decision Algorithm in Patients with Stage I Non-Small Cell Lung Cancer (SWOG-0720, NCT00792701). Cancer, 120, 2343-2351.
[19] Dong, X., Hao, Y., Wei, Y., Yin, Q., Du, J. and Zhao, X. (2014) Response to First-Line Chemotherapy in Patients with Non-Small Cell Lung Cancer According to RRM1 Expression. PLoS ONE, 9, e92320. http://dx.doi.org/10.1371/journal.pone.0092320
[20] Jürgens, J., Engel-Riedel, W., Prickartz, A., Ludwig, C., Schildgen, O., Tillmann, R.L., et al. (2014) Combined Point Mutation in KRAS or EGFR Genes and EML4-ALK Translocation in Lung Cancer Patients. Future Oncology, 10, 529-532. http://dx.doi.org/10.2217/fon.13.194
[21] Azijli, K., van Roosmalen, I.A., Smit, J., Pillai, S., Fukushima, M., de Jong, S., et al. (2014) The Novel Thymidylate Synthase Inhibitor Trifluorothymidine (TFT) and TRAIL Synergistically Eradicate Non-Small Cell Lung Cancer Cells. Cancer Chemotherapy and Pharmacology, 73, 1273-1283. http://dx.doi.org/10.1007/s00280-014-2465-1
[22] Murgu, S. and Colt, H. (2013) Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non-Small-Cell Lung Cancer: Implications for Personalized Medicine. Clinical Lung Cancer, 14, 609-626. http://dx.doi.org/10.1016/j.cllc.2013.04.002
[23] Lindeman, N.I., Cagle, P.T., Beasley, M.B., Chitale, D.A., Dacic, S., Giaccone, G., et al. (2013) Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 8, 823-859. http://dx.doi.org/10.1097/JTO.0b013e318290868f
[24] Murakami, Y., Mitsudomi, T. and Yatabe, Y. (2012) A Screening Method for the ALK Fusion Gene in NSCLC. Frontiers in Oncology, 2, 24. http://dx.doi.org/10.3389/fonc.2012.00024
[25] Institut National du Cancer (INCA). Rapport Scientifique 2010-2011.
[26] Coate, L.E. and Leighl, N.B. (2011) How Affordable Are Targeted Therapies in Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 12, 1-11. http://dx.doi.org/10.1007/s11864-010-0137-x
[27] Rapport budget année 2013 Ministère de la Santé. République Tunisienne. 3-4.
[28] Lewis, J.R., Lipworth, W.L., Kerridge, I.H. and Day, R.O. (2013) The Economic Evaluation of Personalized Oncology Medicines: Ethical Challenges. Medical Journal of Australia, 199, 471-473.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.